Geron Corporation Reports Third Quarter 2020 Financial Results and Current Events
November 05, 2020 16:05 ET
|
Geron Corporation
FOSTER CITY, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the third quarter ended...
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
December 09, 2019 07:30 ET
|
Mustang Bio, Inc.
MB-107 preceded by low-dose busulfan conditioning continues to be well tolerated and results in development of functional immune system in newly diagnosed infants with XSCID Enhanced transduction...
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
December 08, 2019 16:00 ET
|
uniQure Inc.
~ Sustained FIX Activity at Therapeutic Levels1 Up to 50% of Normal at One Year After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~ ~ Zero Bleeds and No Requirement for...
Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
November 06, 2019 09:18 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor,...
Geron Provides Imetelstat Program Update
May 16, 2019 08:00 ET
|
Geron Corporation
MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today provided an update to its 2019 corporate objectives for the imetelstat program. “2019 is off to a good...
Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
December 03, 2018 16:22 ET
|
Geron Corporation
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) --...
Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
December 03, 2018 13:01 ET
|
Apellis Pharmaceuticals, Inc.
- New data on APL-2 demonstrate improvements in hematological parameters in cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA) - CAD patients treated with APL-2 had...
Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
December 03, 2018 06:00 ET
|
Geron Corporation
MENLO PARK, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial...
Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
December 02, 2018 12:01 ET
|
Apellis Pharmaceuticals, Inc.
Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an...
Geron to Host Analyst and Investor Event on December 10, 2018
November 28, 2018 17:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y., on Monday,...